NRC Health (NRC) Q2 2026: Adjusted EPS More Than Doubles the Estimate
As seen on the 24/7 Wall St. homepage on July 28, 2026.
NRC Health crushed earnings with adjusted EPS of 0.31 versus a 0.14 estimate while recurring contract value climbed 11% year-over-year, signaling a strengthening revenue pipeline despite one-time executive transition costs that dragged the bottom line into a net loss.
Continue ReadingShow less
NRC Health posted adjusted earnings per share of $0.31 for Q2 2026, blowing past the $0.14 consensus estimate by more than 121%. The beat continues a trend of outperformance — Q1 2026 also came in at $0.28 against a $0.14 estimate — suggesting the company has built a consistent cushion above Wall Street's expectations over recent quarters.
Revenue of $35.4 million edged out the $34.9 million estimate, a modest but clean top-line beat. More telling for the company's outlook was the 11% year-over-year climb in recurring contract value, a forward-looking metric that points to a deepening pipeline of committed customer spend rather than one-time wins.
The adjusted profit picture was complicated by one-time executive transition costs that pushed the reported bottom line into a net loss for the quarter. Investors will want to track whether those transition charges are fully absorbed in the coming quarters and whether recurring contract value growth continues to accelerate as a signal of durable momentum.
Mentioned: NRC